New skin ointment takes first step toward treating inflammatory conditions

This early-stage trial tests whether a new ointment called YR001 is safe and tolerable when applied to the skin of healthy Chinese adults. The ointment contains a substance that blocks a specific potassium channel involved in immune cell activity. Researchers compare the active ointment to a placebo to check for side effects and measure how much of the drug enters the bloodstream. The study involves 18 participants and lasts about 30 days.